Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AbbVie (NY: ABBV )

162.54 +0.87 (+0.54%)
Official Closing Price Updated: 4:10 PM EDT, Apr 16, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,777,907
Open 162.18
Bid (Size) 162.72 (2)
Ask (Size) 163.78 (1)
Prev. Close 161.67
Today's Range 162.08 - 163.74
52wk Range 130.96 - 182.89
Shares Outstanding N/A
Dividend Yield 3.64%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Steady Income, Steady Growth: 7 Blue-Chip Dividend Stocks to Buy Now
With an already tense situation becoming even more troubling, now’s the time to consider blue-chip dividend stocks to buy. 
Via InvestorPlace
Avalo Therapeutics' Newly Acquired Ex-Eli Lilly Drug Could Stand Out In Competitive Hidradenitis Suppurativa Market, Analyst Upgrades
Unlock the potential of Avalo Therapeutics with AVTX-009, a promising drug for hidradenitis suppurativa. Oppenheimer upgrades to Outperform, foreseeing Phase 2 progress and market distinction. 
Via Benzinga

Performance

YTD
+1.70%
+1.70%
1 Month
-8.94%
-8.94%
3 Month
+0.66%
+0.66%
6 Month
+10.40%
+10.40%
1 Year
+0.84%
+0.84%

More News

Read More
AbbVie's Options Frenzy: What You Need to Know
Via Benzinga
Neumora Stock Hits 2024 Low As Side Effects In Rabbits Torpedo Schizophrenia Drug
Via Investor's Business Daily
Is AbbVie a Millionaire Maker?
Via The Motley Fool
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of AbbVie Inc. (ABBV) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
Smart Money Is Betting Big In ABBV Options
Via Benzinga
What's Going On AbbVie Stock On Friday?
Via Benzinga
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of AbbVie Inc. (ABBV) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for April 2024
Via InvestorPlace
The $5 BILLION Reason Alpine Immune Sciences (ALPN) Stock Is Up 30% Today
Via InvestorPlace
Blindness-Focused LENZ Therapeutics' Investigational Eye Drop Ready To Revolutionize Presbyopia Landscape, Analyst Says
Via Benzinga
AbbVie Unusual Options Activity For April 05
Via Benzinga
Smart Money Is Betting Big In ABBV Options
Via Benzinga
The Law Offices of Frank R. Cruz Announces Investigation of AbbVie Inc. (ABBV) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
3 Dividend Growth Stocks With Yields Above 3% That You Can Buy and Hold for the Next Decade
Via The Motley Fool
3 No-Brainer Dividend Stocks to Buy in April
Via The Motley Fool
Passive Income Perfection: 7 Dividend Stocks to Generate $50,000 Per Year
Via InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
FibroGen Unveils Early Data From Prostate Cancer Candidate, Analyst Advocates Further Exploration In The Landscape
Via Benzinga
The 3 Best Stocks to Buy in April 2024
Via InvestorPlace
Roivant Sciences Stock Flirts With Breakout On 'Extremely Positive' Eye-Disease Study
Via Investor's Business Daily
Got $3,000? 2 Monster Growth Stocks to Buy Right Now Without Hesitation
Via The Motley Fool
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: AdTheorent Holding Company, Inc. (Nasdaq – ADTH), Agiliti, Inc. (NYSE – AGTI), Landos Biopharma, Inc. (Nasdaq – LABP), Fusion Pharmaceuticals Inc. (Nasdaq - FUSN)
From Brodsky & Smith LLC
Via GlobeNewswire
Meet The "Magnificent Seven" of Healthcare Stocks
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.